Key result
A growing body of evidence indicates that cardiac lymphatic vessels may serve as a therapeutic cardiovascular target for conditions like myocardial infarction and atherosclerosis.
Why the study?
Unlike coronary blood vessels, limited information was historically available on the origin and function of cardiac-associated lymphatic vasculature, which may serve as a therapeutic cardiovascular target.
Cardiac lymphatic vessels are emerging as a potential therapeutic target in cardiovascular diseases.
Cardiac lymphatic targeting should not change practice yet; leaves open therapeutic potential in MI and atherosclerosis pending interventional data.
The heart contains a complex network of blood and lymphatic vessels. The coronary blood vessels provide the cardiac tissue with oxygen and nutrients and have been the major focus of research for the past few decades. Cardiac lymphatic vessels, which consist of lymphatic capillaries and collecting lymphatic vessels covering all layers of the heart, transport excess fluid from the interstitium and play important roles in maintaining tissue fluid balance. Unlike for the coronary blood vessels, until a few years ago, not much information was available on the origin and function of the cardiac-associated lymphatic vasculature. A growing body of evidence indicates that cardiac lymphatic vessels (lymphatics) may serve as a therapeutic cardiovascular target.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2019) conducted a review in Cardiovascular diseases (atherosclerosis, myocardial infarction). Lymphatic vasculature targeting was evaluated. A growing body of evidence indicates that cardiac lymphatic vessels may serve as a therapeutic cardiovascular target for conditions like myocardial infarction and atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: